SX-682, another CXCR1/2 inhibitor is being investigated in pancreatic ductal adenocarcinoma (PDAC) and metastatic melanoma (NCT04477343 and NCT03161431), whereas the selective CXCR2 inhibitor AZD5069 is being evaluated in metastatic castration-resistant prostate cancer (NCT03177187). The gene discussed is CXCR1; the disease is prostate cancer.